Combining LGR5- and MET-targeting ADCs with different payloads significantly delays tumor relapse and prolongs survival in preclinical colorectal cancer models.
- Open access
HER2/EGFR in Cancer Research
Moving in bioRxiv, Cancer Discovery, Cancer Research and Nature.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 7
Add HER2/EGFR in Cancer Research as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in HER2/EGFR in Cancer Research
Newest first · last 60 days
CDK2 inhibitor PF-07104091 achieves disease stabilization in CDK4/6 inhibitor-resistant HR+/HER2- metastatic breast cancer regardless of RB status, with responses linked to TP53 retention.
- Open access
Modular in vivo antibody-ADC click strategy enhances tumor targeting and overcomes resistance in heterogeneous cancers, showing improved activity in preclinical models.
- Open access
IL1RAP antibody-drug conjugates effectively target primary and metastatic tumors in multiple oncofusion-driven cancers, causing tumor regression and reducing metastasis.
- Open access
- 1 cites
Add HER2/EGFR in Cancer Research as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6183
- medRxiv1716
- PNAS472
- Sci Adv398
- JAMA274
- Environ Res230
- BMJ200
- Nat Commun171
- Environ Pollution165
- Nature161
- NEJM146
- Science141
- Lancet132
- Cell Rep130
- Curr Biol108
- J Exp Bot108
- mBio107
- Plant Cell Environ107
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3